Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I too would like an explanation of who was in that 3 mil share trade. Both sides.
In my buy this morning it took 8 trades to fill 1000 shares.
I bought a little more this morning. HALO’s price target has been to 65 by Morgan Stanley.
3 mil shares traded today. 637K AH.
5 new Form 4s filed.
https://ir.avidbio.com/sec-filings
Total volume 651K
Off-Exchange Short Volume 492,400 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 79.26% - source: FINRA (inc. Dark Pool volume)
Buyvolume 389K vs 227K sell volume.
https://ih.advfn.com/stock-market/NASDAQ/avid-bioservices-CDMO/trades
AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR SECOND QUARTER ENDED OCTOBER 31, 2022 AND RECENT DEVELOPMENTS
-- Recorded Second Quarter Revenue of $34.8 Million --
-- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year --
-- Mammalian Cell Facilities and Cell and Gene Therapy Facility Expansions Continue on Schedule --
-- Revenue Guidance for Fiscal 2023 Increased to $145 to $150 Million --
TUSTIN, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the second quarter and six months ended October 31, 2022.
Highlights from the Quarter Ended October 31, 2022, and Other Events:
“The consistent execution by our team has strengthened and expanded our customer base, and significantly improved the company’s financial position as compared to prior years. Our topline revenues remain strong and our backlog continues to show strong growth over the prior year. The investment in our business development team is already showing positive results ahead of the completion of our new capacity and services soon to come online. We fully expect this momentum to continue and for all of these reasons, I am pleased to report that Avid is increasing its revenue guidance for the full fiscal year 2023 to between $145 million and $150 million,” stated Nick Green, president and chief executive officer of Avid Bioservices.
“With respect to our facilities and capabilities expansions, work continues to advance according to plan. During the second quarter, we continued to make progress with our cell and gene therapy expansion. We have already launched the analytical and process development capabilities for this business which has allowed us to escalate our dialog with prospective new customers. We are pleased to report that our first customer is already onboarding in this facility. With respect to the GMP suites for our cell and gene therapy business, construction continues on schedule and we expect them to be completed by mid-calendar 2023.
“Likewise, our mammalian cell business capacity expansion is progressing as planned. During the first quarter, much of the downstream equipment was positioned in the Myford facility and validation of this equipment was initiated. During the second quarter, we installed the upstream equipment. As we stand today, the facility is largely mechanically complete and is currently undergoing qualification and validation. We remain on schedule for release to operations during the first quarter of calendar 2023. And finally, expansion of our process development capacity is well underway. The addition of this new capacity is ideally timed as our updated revenue guidance puts our capacity utilization at close to 90% of our current capacity.
“Based on the company’s performance during the first six months, we anticipate that fiscal 2023 will be another strong year for Avid. The company’s strategic transformation is well underway, and we look forward to achieving the milestones that will position us for consistent growth in the future.”
Financial Highlights and Guidance
The company is increasing full year revenue guidance for fiscal 2023 from $140 to $145 million to $145 and $150 million.
Revenues for the second quarter of fiscal 2023 were $34.8 million, representing a 33% increase compared to $26.1 million recorded in the prior year period. For the first six months of fiscal 2023, revenues were $71.4 million, a 26% increase compared to $56.9 million in the prior year period. For both the quarter and the year-to-date periods, the increase in revenues can primarily be attributed to increases in process development and manufacturing revenues as compared to the prior year periods.
As of October 31, 2022, revenue backlog was $147 million, representing a net increase of 23% compared to $120 million at the end of second quarter fiscal 2022. The company expects to recognize the majority of this backlog over the next twelve months.
Gross margin for the second quarter of fiscal 2023 was 12%, compared to a gross margin of 35% for the second quarter of fiscal 2022. Gross margin for first six months of fiscal 2023 was 19%, compared to a gross margin of 36% for the same period during fiscal 2022. During fiscal 2023, growth related costs including labor, overhead and depreciation, represented incremental decreases in margin of approximately 11% and 9%, for the second quarter and year-to-date, respectively, split approximately evenly between mammalian and cell and gene therapy operations. Additionally, prior year’s margins included benefits from unutilized capacity fees. Excluding all of these factors, our second quarter and year-to-date gross margins were approximately in-line with the prior year periods.
Selling, general and administrative (“SG&A”) expenses for the second quarter of fiscal 2023 were $6.8 million, an increase of 36% compared to $5.0 million recorded for the second quarter of fiscal 2022. SG&A expenses for the first six months of fiscal 2023 were $13.2 million, an increase of 39% as compared to $9.5 million recorded in the prior year period. The increases in SG&A for both the second quarter and the year-to-date periods were primarily due to increases in compensation and benefits, legal, accounting and other professional expenses.
For the second quarter of fiscal 2023, the company recorded a net loss of $1.2 million or $0.02 per basic and diluted share, as compared to net income of $3.5 million or $0.06 per basic and diluted share, for the second quarter of fiscal 2022. For the first six months of fiscal 2023, the company recorded net income of $0.4 million or $0.01 per basic and diluted share, as compared to net income of $9.8 million or $0.16 and $0.15 per basic and diluted share, respectively, during the same prior year period.
Avid reported $77.3 million in cash and cash equivalents as of October 31, 2022, compared to $126.2 million as of April 30, 2022.
More detailed financial information and analysis may be found in Avid Bioservices’ Quarterly Report on Form 10-Q, which will be filed with the Securities and Exchange Commission today.
Recent Corporate Developments
The company’s commercial team signed multiple new orders during the second quarter, totaling approximately net $26 million. These orders are with new and existing customers, and span all areas of the business, from process development to commercial manufacturing.
During the second quarter, the company strengthened its management team.
Michael Alston, Jr. was promoted to the position of vice president, operations, having previously served as Avid’s director of project engineering. Mr. Alston has more than 15 years of experience spanning operational and capital management responsibilities supporting CGMP manufacturing, facilities, engineering, and environmental, health and safety functions.
Oksana Lukash, joined Avid as vice president, people. Ms. Lukash has more than 20 years of human resources experience. Prior to joining Avid, Ms. Lukash served as vice president, people & culture at Oncocyte Corporation. During her three-year tenure with the company, she was instrumental in driving three acquisitions and the successful integration of the acquired entities.
The company continues to make progress with all of its expansion projects, as well as the construction of its new dedicated cell and gene therapy facility. The company currently expects to complete the second phase of its Myford expansion, which includes both upstream and downstream CGMP manufacturing suites, by the end of the first quarter of calendar 2023. With respect to the cell and gene therapy business, the company brought its process and analytical development capacity online in June 2022. The company remains on track to bring the CGMP manufacturing suites online by mid-calendar 2023. Please visit the Avid Bioservices website Facilities page for more information about the company’s expansions and videos documenting progress ( https://avidbio.com/expansion-updates/ ).
Statement Regarding Use of Non-GAAP Financial Measures
The company uses certain non-GAAP financial measures such as non-GAAP adjusted net income (loss), free cash flow, as well as adjusted EBITDA. The company uses these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. The company believes that they provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by management in our financial and operational decision making. These non-GAAP financial measures exclude amounts that the company does not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and our senior management. The company computes non-GAAP financial measures using the same consistent method from quarter to quarter and year to year, and may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures.
The company reports non-GAAP financial measures in addition to, and not as a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. generally accepted accounting principles (GAAP). These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. The company believes that non-GAAP financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures, and encourages investors to carefully consider our results under GAAP, as well as the supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business.
Non-GAAP net income (loss) excludes stock-based compensation; business transition and related costs including corporate initiatives into new business activities such as initial start-up costs related to our expansion into viral vectors for the cell and gene therapy sector of the market, and severance and related expenses; non-cash interest expense on convertible senior notes for the accretion of the issuance costs associated with our convertible senior notes; and other income or expense items and is adjusted for income taxes. Adjusted EBITDA excludes non-cash operating charges for stock-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, and income tax expense or benefit and is adjusted for income taxes. For the reasons explained above, adjusted EBITDA also excludes certain business transition and related costs. The company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital.
Additionally, non-GAAP net income (loss) and adjusted EBITDA are key components of the financial metrics utilized by the company’s compensation committee to measure, in part, management’s performance and determine significant elements of management’s compensation. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP financial measures included at the end of this press release.
Webcast
Avid will host a webcast this afternoon, December 6, 2022, at 4:30 PM EST (1:30 PM PST).
To listen to the live webcast, or access the archived webcast, please visit: https://ir.avidbio.com/investor-events .
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Altravue Capital filed a 13G, maybe related to the large EOD trade? Their 9/30 filing per NASDAQ.Com:
ALTRAVUE CAPITAL, LLC 09/30/2022 2,684,960 -50,280 -1.838% $40,248
Avid Bioservices, Inc. View: Download DOC Download PDF
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
AVID BIOSERVICES, INC.
(Name of Issuer)
Common
(Title of Class of Securities)
05368M106
(CUSIP Number)
November 29th, 2022
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[X] Rule 13d-1(b)
[_] Rule 13d-1(c)
[_] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting persons
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities Exchange
Act of 1934 (Act) or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
SCHEDULE 13G
CUSIP No. 05368M106
1
Names of Reporting Persons
AltraVue Capital, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a) [ ]
(b) [ ]
3
Sec Use Only
4
Citizenship or Place of Organization
Delaware, US
Number of
Shares
Beneficially
Owned by Each
Reporting Person
With:
5
Sole Voting Power
1,924,807
6
Shared Voting Power
1,185,493
7
Sole Dispositive Power
3,110,300
8
Shared Dispositive Power
0
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,110,300
10
Check box if the aggregate amount in row (9) excludes certain
shares (See Instructions)
[ ]
11
Percent of class represented by amount in row (9)
5.003%
12
Type of Reporting Person (See Instructions)
IA
Item 1.
(a) Name of Issuer: Avid Bioservices Inc.
(b) Address of Issuer?s Principal Executive Offices:
14191 Myford Road
Tustin, CA 92780
Item 2.
(a) Name of Person Filing: AltraVue Capital, LLC
(b) Address of Principal Business Office or, if None, Residence:
11747 NE 1st Street, Suite 205
Bellevue, WA 98005-3018
(c) Citizenship: USA
(d) Title and Class of Securities: Common
(e) CUSIP No.: 05368M106
Item 3. If this statement is filed pursuant to ?? 240.13d-1(b)
or 240.13d-2(b) or (c), check whether the person filing is a:
(a) [_] Broker or dealer registered under Section 15 of the Act;
(b) [_] Bank as defined in Section 3(a)(6) of the Act;
(c) [_] Insurance company as defined in Section 3(a)(19) of the Act;
(d) [_] Investment company registered under Section 8 of the
Investment Company Act of 1940;
(e) X An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) [_] An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F);
(g) [_] A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
(h) [_] A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [_] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment Company Act of 1940;
(j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
(k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as
a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please
specify the type of institution:
____
Item 4. Ownership
(a) Amount Beneficially Owned: 3,110,300
(b) Percent of Class: 5.003%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 1,924,807
(ii) Shared power to vote or to direct the vote: 1,185,493
(iii) Sole power to dispose or to direct the disposition of: 3,110,300
(iv) Shared power to dispose or to direct the disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following [ ].
Item 6. Ownership of more than Five Percent on Behalf of Another Person.
Item 7. Identification and classification of the subsidiary which acquired the
security being reported on by the parent holding company or control person.
Item 8. Identification and classification of members of the group.
Item 9. Notice of Dissolution of Group.
Item 10. Certifications.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this
statement is true, complete, and correct.
Dated: November 29, 2022
/s/ Signature
Tom Parkhurst / COO & CCO
Name/Title
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is
signed on behalf of a person by his authorized representative (other than an
executive officer or general partner of this filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed
with the statement, provided, however, that a power of attorney for this
purpose which is already on file with the Commission may be incorporated by
reference. The name and any title of each person who signs the statement
shall be typed or printed beneath his signature.
Attention: Intentional misstatements or omissions of fact constitute Federal
criminal violations (See 18 U.S.C. 1001).
Page 1 of 1
1297544.3
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022
November 29, 2022 at 4:05 PM EST
Download PDF
TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2023 on December 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the second quarter and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.
About Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
HALO is on a tear, up 2.78 to 57.45.
Last year it was December 7.
Avid Bioservices Appoints Oksana Lukash as Vice President, People
November 16 2022 - 08:05AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial organizations across a range of industries.
Prior to joining Avid, Ms. Lukash served as vice president, people & culture at Oncocyte Corporation, a precision diagnostics company. During her three year tenure with the company, she was instrumental in driving three acquisitions and the successful integration of the acquired entities. Ms. Lukash is also credited with growing Oncocyte’s employee base by nearly 600%, with less than 5% turnover and securing recognition for the company multiple times as a “Best Places to Work” locally and national. Throughout her career, she has also held senior human resources roles with several other leading life science companies including Avanir Pharmaceuticals, Agendia, and Clarient. Ms. Lukash is also an active member of Chief network, a private network built to drive more women into positions of leadership, as well as a vice chair of the board for the Dee Dee Jackson Foundation, an organization that connects those who have a commonality in grief.
“We are excited to welcome Oksana and her track record of successfully building and supporting workforces and creating best-in-breed cultures at a range of leading companies within the life science industry to Avid,” said Nick Green, president and chief executive officer of Avid Bioservices. “Her strategic, tech-savvy approach is an ideal fit for the company and we look forward to the contributions that she will make in continuing to enhance our team and optimize the workplace in which they drive Avid’s success.”
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
Yes. NASDAQ WAS 100.35 previously.
According to Fintel
Institutional Shares (Long) 74,746,917 - 120.23% (ex 13D/G)
According to NASDAQ
Institutional Ownership 104.10%
T Rowe Price new position
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. 09/30/2022 1,642,093 1,642,093 New $25,223
I totally agree with you.
FMR LLC (Fidelity) has greatly reduced their position.
FMR LLC 06/30/2022 6,088,025
New 13G filed showing 2,978,979 shares owned.
Institutional investment 116.69% now.
https://fintel.io/so/us/cdmo
HALO up over $4.
The usual premarket games. Down .67 on 5 shares.
HALO had excellent results up 1.37 AH.
Third Quarter Revenue Increased 80% YOY to $209 Million, with GAAP Diluted Earnings per Share of $0.44 and Non-GAAP Diluted Earnings per Share of $0.741
Record Third Quarter Royalty Revenue Increased 70% YOY to $99.6 Million
Reiterating 2022 Revenue Guidance of $655 Million to $685 Million, Representing 48%-55% Growth over Reported 2021 Revenue
Another source:
Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.23, revenue of $208.98M beats by $17.81M
It was from Friday, at 3:25pm. Reg SHO list
CDMO,"Avid Bioservices, Inc.",R,11/4/2022 3:25:04 PM
I just saw the tweet and posted it, but it doesn’t appear that CDMO dropped 10% today for the circuit breaker to kick in. Therefore, the tweet and my prior post may be in error.
AVID BIOSERVICES INC - CDMO
Short sale restricted for 2022-11-07
FWIW, I bought some at 12.99. Nick and the boys should make some open market purchases here.
Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference
November 02 2022 - 04:05PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Credit Suisse 31st Annual Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will deliver a corporate presentation at the conference, which will take place November 7-10, 2022, in Rancho Palos Verdes, CA.
Details of the company’s participation are as follows:
Credit Suisse 31st Annual Healthcare Conference
Conference Date: November 7-10, 2022
Presentation Time/Date: 12:50 - 1:20 p.m. Pacific on Wednesday, November 9, 2022
Location: Terranea Resort, Rancho Palos Verdes, CA
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Fintel has institutional investment at 115.48% up From 113.86% earlier today.
Jennison Associates increased their ownership 53%, totaling 2.877 mil shares.
Another
10/31/2022 11:00:36 EDT F 17.02 299604 NDD
Large red trade
10/31/2022 10:40:13 EDT F 17.00 359619 NDD
Avid Bioservices Inc
NASDAQ
17.73 0.61 (3.56%)
Oct 28, 2022, 3:59:54 PM EDT
Day's Range N/A - N/A
52 Week Range 11.30 - 34.51
Pharmaceutical Preparatio...
Short Interest shares - source: NASDAQ
Short Interest Ratio 9.10 Days to Cover
Short Interest % Float 7.87% - source: NASDAQ (short interest), Capital IQ (float)
Off-Exchange Short Volume 46,741 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 69.27% - source: FINRA (inc. Dark Pool volume)
Off exchange short volume up from 63+% yesterday
Short Interest Ratio 7.23 Days to Cover
Short Interest % Float 7.87% - source: NASDAQ (short interest), Capital IQ (float)
Off-Exchange Short Volume 141,092 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 63.23% - source: FINRA (inc. Dark Pool volume)
From Fintel.io
Short Interest Ratio 6.80 Days to Cover
Short Interest % Float 8.83% - source: NASDAQ (short interest), Capital IQ (float)
Off-Exchange Short Volume 85,622 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 21.81% - source: FINRA (inc. Dark Pool volume)
Nah. No credits for stupidity.
As of 9/30 it was 8.83% according to TDAmeritrade. Quite a jump. Seems like someone is buying in?
And yet, still more buying than selling. 75K vs 68 K.
Buy volume 296K sell volume 295K
https://ih.advfn.com/stock-market/NASDAQ/avid-bioservices-CDMO/trades
TOMI to Install Custom Engineered Integrated iHP System in Avid Bioservices, Inc. Viral Vector Manufacturing Facility in California
October 10 2022 - 08:30AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP), today announced that it has recently received a purchase order for an iHP Custom Engineered System (CES) from Avid Bioservices, Inc. (Avid) for implementation in Avid’s new purpose-built viral vector development and manufacturing facility in Costa Mesa, California.
Avid is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. With the rapidly growing cell and gene therapy market, Avid is constructing a 53,000 square foot world-class CGMP manufacturing building dedicated to viral vector development and manufacturing. SteraMist has been chosen by Avid as its preferred decontamination method due to SteraMist’s ability to rapidly decontaminate and disinfect the area approximately four times faster than the competition, and its low percentage (7.8%) hydrogen peroxide BIT solution that provides superior material compatibility on surfaces.
During site development, a SteraMist iHP Custom Engineered System will be implemented within four (4) GMP manufacturing suites. This will require eleven (11) applicators with a single control panel and a 55-gallon BIT solution container. Earlier this month, the TOMI team began working with Avid’s team on planning the installation, which is projected to be finalized in the first half of 2023.
Atef Khezri, executive director of viral vector manufacturing at Avid Bioservices, said, “Our team at Avid looks forward to working with TOMI on the installation of the custom decontamination system. With the need for an effective and robust decontamination system to provide a sterile environment and a quick turnaround time, SteraMist was the evident solution.”
“The TOMI team put forth a great effort to win this bid. Avid conducted extensive due diligence which we were able to report successfully,” Elissa J. (E.J.) Shane, Chief Operating Officer at TOMI states. “We are well prepared for this project and eager to work with another innovative company for a seamless install of an iHP Custom Engineered System. TOMI looks forward to future opportunities to expand SteraMist throughout other areas of the facility.”
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com
About?Avid Bioservices, Inc.
Avid Bioservices (NASDAQ: CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to anticipated financial performance and operating results, including result for the March quarter in 2022; expected growth in sales and market demand; intent to sell shares by the management; revenue opportunities of CES products and timing of revenue recognition; growth strategies of the company; anticipated manufacturing capability; and trading price of common stock. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Jennifer Belodeau
IMS Investor Relations
tomi@imsinvestorrelations.com
Primary Logo
Poor cf. nothing to gloat about today.
2 trades premarket
Date/Time Price Shares Exch/Mkt
10/03/2022 8:01:23 EDT I 20.45 4 CBOE EDGX
10/03/2022 7:44:45 EDT W 19.12 1610
10:44:28 $ 19.81 120,000
Will we see higher volume due to quarter end adjustments?